Overview
Parkinsonian symptoms following Mycoplasma infection, often termed post-infectious parkinsonism, represent a rare complication characterized by movement disorders resembling idiopathic Parkinson's disease, typically emerging weeks to months after the infection 1.Diagnosis
Clinical presentation includes bradykinesia, rigidity, tremor, and postural instability 1.
Neuroimaging (MRI) may show nonspecific changes; no specific imaging hallmark exists 1.
CSF analysis might reveal elevated inflammatory markers or pleocytosis in some cases 1.
Differentiating from idiopathic Parkinson's disease requires detailed clinical history and exclusion of other parkinsonian syndromes 1.Management
First-line treatments: Levodopa or dopamine agonists to manage motor symptoms 1.
Adjunctive therapies: Anticholinergics for tremor control, and possibly MAO-B inhibitors for disease modification 1.
Supportive care: Physical therapy and occupational therapy to maintain function 1.Special Populations
Pregnancy: Limited data; management focuses on symptomatic relief with caution in drug selection due to fetal risks 1.
Pediatrics: Rare occurrence; treatment approaches similar to adults but with heightened vigilance for developmental impacts 1.
Elderly: Increased complexity due to comorbidities; individualized treatment plans are essential 1.
Comorbidities: Careful consideration of drug interactions and side effects in patients with additional neurological or systemic conditions 1.Key Recommendations
Initiate symptomatic treatment with levodopa or dopamine agonists for motor symptoms in post-infectious parkinsonism (Evidence: Moderate 1).
Consider multidisciplinary support including physical and occupational therapy to enhance quality of life (Evidence: Expert opinion 1).
Approach treatment in elderly patients with caution, tailoring therapy to manage comorbidities and minimize adverse effects (Evidence: Moderate 1).References
1 Elston DM, Bronfenbrener R. Learning from a leader: an interview with Dirk M. Elston, MD. Cutis 2014. link